Danaher Co. (NYSE:DHR) is McCollum Christoferson Group LLC’s 9th Largest Position

17 Oct 2024, 18:54 by Kim Johansen · The Markets Daily

McCollum Christoferson Group LLC lowered its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 0.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,874 shares of the conglomerate’s stock after selling 116 shares during the period. Danaher comprises 3.3% of McCollum Christoferson Group LLC’s investment portfolio, making the stock its 9th biggest position. McCollum Christoferson Group LLC’s holdings in Danaher were worth $11,364,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Tsfg LLC grew its stake in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher during the 2nd quarter valued at about $25,000. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter valued at about $25,000. Redmont Wealth Advisors LLC purchased a new stake in Danaher during the 1st quarter valued at about $30,000. Finally, MFA Wealth Advisors LLC acquired a new position in Danaher in the 2nd quarter valued at about $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $267.99 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The stock has a market capitalization of $198.50 billion, a PE ratio of 45.42, a P/E/G ratio of 4.49 and a beta of 0.83. The firm has a 50 day moving average of $270.53 and a two-hundred day moving average of $259.65.

Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the company posted $2.05 EPS. The firm’s revenue was down 2.9% compared to the same quarter last year. On average, research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Danaher in a report on Friday, September 6th. Stifel Nicolaus boosted their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. TD Cowen boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Finally, Stephens assumed coverage on shares of Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price on the stock. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $282.12.

Check Out Our Latest Research Report on Danaher

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.